{"generic":"Somatrem","drugs":["Protropin","Somatrem"],"mono":{"0":{"id":"559300-s-0","title":"Generic Names","mono":"Somatrem"},"1":{"id":"559300-s-1","title":"Dosing and Indications","sub":{"1":{"id":"559300-s-1-5","title":"Pediatric Dosing","mono":"<b>Growth hormone deficiency:<\/b> 0.3 mg\/kg\/WEEK IM\/SUBQ in equal divided daily doses"},"3":{"id":"559300-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Growth hormone deficiency<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Decreased body growth - Down syndrome<\/li><li>Decreased body growth - Juvenile chronic arthritis<\/li><li>Renal function impairment with growth failure<\/li><li>Short stature disorder, Idiopathic<\/li><li>Turner syndrome<\/li><\/ul>"}}},"3":{"id":"559300-s-3","title":"Contraindications\/Warnings","sub":[{"id":"559300-s-3-9","title":"Contraindications","mono":"<ul><li>active neoplasia<\/li><li>acute critical illness due to complications following open-heart surgery or abdominal surgery<\/li><li>acute respiratory failure<\/li><li>closed epiphyses<\/li><li>hypersensitivity to somatrem products or benzyl alcohol<\/li><li>patients with multiple accidental trauma<\/li><\/ul>"},{"id":"559300-s-3-10","title":"Precautions","mono":"<ul><li>diabetes mellitus or family history of diabetes<\/li><li>endocrine disorders<\/li><li>geriatric use<\/li><li>history of an intracranial lesion<\/li><li>patients undergoing rapid growth<\/li><li>scoliosis (progression can occur)<\/li><\/ul>"},{"id":"559300-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"559300-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"559300-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain<\/li><li><b>Immunologic:<\/b>Antibody development<\/li><\/ul>"},"6":{"id":"559300-s-6","title":"Drug Name Info","sub":{"0":{"id":"559300-s-6-17","title":"US Trade Names","mono":"Protropin<br\/>"},"2":{"id":"559300-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Pituitary Hormone, Anterior<\/li><\/ul>"},"3":{"id":"559300-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"559300-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>may give SubQ or IM; rotate injection sites<\/li><li>reconstitute at room temperature in Bacteriostatic Water for Injection; do not shake, gently swirl<\/li><li>newborns and patients sensitive to benzyl alcohol; reconstitute in Sterile Water for Injection<\/li><\/ul>"},"10":{"id":"559300-s-10","title":"Monitoring","mono":"<ul><li>growth rate (bone age)<\/li><li>glucose levels, serum levels of inorganic phosphorus, alkaline phosphatase, and parathyroid hormone<\/li><li>initial and periodic funduscopic examination (for intracranial hypertension)<\/li><li>signs and symptoms of slipped capital femoral epiphyses<\/li><\/ul>"},"12":{"id":"559300-s-12","title":"Toxicology","sub":[{"id":"559300-s-12-31","title":"Clinical Effects","mono":"<b>SOMATREM<\/b><br\/>OVERDOSE: Somatrem is a growth hormone derived from recombinant DNA technology. Overdose data are limited. ADVERSE EFFECTS: Peripheral edema, pancreatitis, hypo- and hyperglycemia, hypothyroidism, intracranial hypertension, carpal tunnel syndrome, gynecomastia and increased alkaline phosphatase have been reported following the therapeutic use of growth hormones. Somatrem for injection is administered after reconstitution with bacteriostatic water for injection containing benzyl alcohol as an antimicrobial preservative.  Benzyl alcohol has been associated with toxicity in newborns.<br\/>"},{"id":"559300-s-12-32","title":"Treatment","mono":"<b>SOMATREM<\/b><br\/><ul><li>Decontamination: Not indicated. IM or subQ administration.<\/li><li>Support: Treatment is symptomatic and supportive; no antidote is available.<\/li><li>Monitoring of patient: Obtain baseline blood glucose level; repeat as indicated. Monitor vital signs and thyroid function following an overdose.<\/li><\/ul>"},{"id":"559300-s-12-33","title":"Range of Toxicity","mono":"<b>SOMATREM<\/b><br\/>TOXICITY: A minimum toxic dose has not been established. THERAPEUTIC: Pediatric: 0.30 mg\/kg\/week (approximately 0.90 International Units\/kg) IM or subQ in equally divided daily doses. <br\/>"}]},"13":{"id":"559300-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report signs\/symptoms of slipped capital femoral epiphyses (limp, leg\/hip pain), intracranial hypertension (visual changes, headache, nausea, vomiting), or glucose intolerance.<\/li><li>Patient should contact healthcare professional if growth slows too much or ceases.<\/li><li>This drug may be used intramuscularly or subcutaneously. If self-administered, advise patient on proper administration technique and to rotate injection sites.<\/li><li>Tell patient that drug therapy may continue until patient has stopped growing and achieves final height.<\/li><\/ul>"}}}